Asthma is one of the most common paediatric chronic diseases, affecting up to 30% of children in the Western world. Respiratory tract infections caused either by viruses or bacteria are important factors which may exacerbate the course of the disease in at risk populations. Asthma experts postulated that oral immunostimulation with bacterial lysate, could help controlling the course of asthma and represent an interesting tool for asthma management.
Lallemand Pharma has invested in recent years in clinical research on PMBL® sublingual tablets and its benefits in asthma course and sponsored a randomized clinical trial the EOLIA study (Efficiency Of Lysate In Asthmatic children). The final report of the study is available now .
